Study Sample
This manuscript is related to a large retrospective, populationbased
cohort study in which we included children and adolescents
with AML diagnosed and treated in each Canadian province
except Saskatchewan.[5] We included children and adolescents
#18 years with de novo AML diagnosed between January 1, 1995
and December 31, 2004. Children with Down syndrome were also
included. We excluded those with acute promyelocytic leukemia,
secondary AML, and